Literature DB >> 16765177

Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology.

John M Hollingsworth1, David C Miller, Rodney L Dunn, Jeffrey S Montgomery, William W Roberts, Khaled S Hafez, J Stuart Wolf.   

Abstract

OBJECTIVES: To address the concern that laparoscopic radical nephrectomy (LRN) is being applied in cases of small renal masses in which nephron-sparing surgery (NSS) might be more appropriate.
METHODS: From 1998 to 2003, 381 consecutive patients underwent 391 procedures at our institution for renal cell carcinoma, of which 336 were for organ-confined tumors. The temporal trends in the application of LRN and NSS were assessed relative to the clinical stage.
RESULTS: During the transition from early (1998 to 2000) to late (2001 to 2003) experience with laparoscopy, the use of LRN among patients with Stage T1a (4 cm or smaller) lesions remained infrequent (21% and 20%, respectively). In contrast, LRN increased among patients with larger lesions during this same interval (Stage T1b, 36% versus 56%, P = 0.017 and Stage T2, 24% versus 41%, P = 0.056). Concurrently, the use of NSS (open surgical or laparoscopic partial nephrectomy) increased for both Stage T1a (25% and 31% versus 34% and 37%, P = 0.082) and T1b (8% and 6% versus 19% and 5%, P = 0.017) tumors. Multivariate analysis demonstrated that the use of both NSS and LRN increased significantly with time (P = 0.002 and P = 0.001, respectively). Neither NSS nor LRN were associated with a greater risk of perioperative complications relative to radical or open surgery (P >0.05 for both).
CONCLUSIONS: During a 6-year period at our institution, most Stage T1a lesions were managed with NSS, and a significant increase occurred in the use of NSS for Stage T1b tumors, despite the concurrent increasing application of LRN. These findings suggest that oncologic, rather than technologic, concerns were determining our practice patterns.

Entities:  

Mesh:

Year:  2006        PMID: 16765177     DOI: 10.1016/j.urology.2006.01.008

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Tumor enucleoresection in robot-assisted partial nephrectomy.

Authors:  Alexandre Mottrie; Nikolaos Koliakos; Geert DeNaeyer; Pieter Willemsen; Nicolo Buffi; Peter Schatteman; Etienne Fonteyne
Journal:  J Robot Surg       Date:  2009-03-13

2.  Ubenimex enhances the radiosensitivity of renal cell carcinoma cells by inducing autophagic cell death.

Authors:  Shuai Liu; Xiaoqing Wang; Jiaju Lu; Liping Han; Yongfei Zhang; Zheng Liu; Sentai Ding; Zhao Liu; Dongbin Bi; Zhihong Niu
Journal:  Oncol Lett       Date:  2016-08-22       Impact factor: 2.967

3.  Retroperitoneoscopic radical nephrectomy with a small incision for renal cell carcinoma: comparison with the conventional method.

Authors:  Hiroki Ito; Kazuhide Makiyama; Takashi Kawahara; Futoshi Sano; Takayuki Murakami; Narihiko Hayashi; Yasuhide Miyoshi; Noboru Nakaigawa; Masahiro Yao; Yoshinobu Kubota
Journal:  J Negat Results Biomed       Date:  2011-08-16

4.  Diffusion of surgical innovation among patients with kidney cancer.

Authors:  David C Miller; Christopher S Saigal; Mousumi Banerjee; Jan Hanley; Mark S Litwin
Journal:  Cancer       Date:  2008-04-15       Impact factor: 6.860

5.  A modified adrenal gland-sparing surgery based on retroperitoneal laparoscopic radical nephrectomy.

Authors:  Zhenyu Xu; Zhengyu Zhang; Jianping Gao; Zhifeng Wei; Xiaofeng Xu; Jie Dong; Hao Tang; Xiaoming Yi; Chaopeng Tang; Wenquan Zhou
Journal:  World J Surg Oncol       Date:  2014-06-05       Impact factor: 2.754

6.  The changing scenario of nephron sparing approaches to treat renal tumors: Making a case to save the nephrons!

Authors:  Krishnanath Gaitonde
Journal:  Indian J Urol       Date:  2009 Oct-Dec

7.  Costunolide Induces Autophagy and Apoptosis by Activating ROS/MAPK Signaling Pathways in Renal Cell Carcinoma.

Authors:  Dian Fu; Ding Wu; Wen Cheng; Jianping Gao; Zhengyu Zhang; Jingping Ge; Wenquan Zhou; Zhenyu Xu
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.